Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholesterol. How low should we go?

Hassan Chamsi-Pasha1

  • 1Director of Non-invasive Cardiology, King Fahd Armed Forces Hospital, PO Box 9862, Jeddah 21159, Kingdom of Saudi Arabia. drhcpasha@hotmail.com

Saudi Medical Journal
|March 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical Challenges and Current Opportunities of Artificial Intelligence in Cardiology.

Avicenna journal of medicine·2025
Same author

Ethical dilemmas in the era of COVID-19.

Avicenna journal of medicine·2020
Same author

Minimizing nocebo effect: Pragmatic approach.

Avicenna journal of medicine·2017
Same author

Do not resuscitate, brain death, and organ transplantation: Islamic perspective.

Avicenna journal of medicine·2017
Same author

Slowing the Tide of Alcohol Use Disorders.

Journal of religion and health·2016
Same author

Critical congenital heart disease screening.

Avicenna journal of medicine·2016

New guidelines recommend lower LDL-cholesterol targets for high-risk patients. Intensive statin therapy, potentially with ezetimibe, is crucial for achieving these goals and preventing coronary heart disease.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • The National Cholesterol Education Program (NCEP) updated Adult Treatment Panel (ATP) III guidelines.
  • Guidelines emphasize more intensive cholesterol treatment for high-risk patients, particularly for coronary heart disease (CHD).
  • Lower low-density lipoprotein (LDL)-cholesterol levels are increasingly recognized as beneficial for high-risk individuals.

Purpose of the Study:

  • To review updated NCEP ATP III guidelines for cholesterol management.
  • To discuss the benefits of intensive LDL-cholesterol lowering in high-risk and very high-risk patients.
  • To highlight the role of statins and combination therapies, including ezetimibe, in achieving treatment targets.

Main Methods:

  • Review of recent clinical trials and NCEP ATP III guidelines.

Related Experiment Videos

  • Analysis of LDL-cholesterol treatment targets for different risk categories.
  • Evaluation of pharmacological interventions, including statins and ezetimibe.

    • Main Results:

    • NCEP recommends LDL-cholesterol <100 mg/dL for high-risk CHD patients.
    • Therapeutic option for very high-risk patients: LDL-cholesterol <70 mg/dL.
    • Coadministration of ezetimibe with statins achieved a 23% greater LDL-cholesterol reduction compared to statin monotherapy.

    Conclusions:

    • Intensive lipid-lowering therapy is recommended for patients with acute coronary syndrome.
    • Achieving very low LDL-cholesterol levels often necessitates high-dose statins or combination therapy.
    • Despite guidelines, many hyperlipidemic patients remain undertreated, underscoring the need for improved adherence and treatment strategies.